<DOC>
	<DOCNO>NCT01591902</DOCNO>
	<brief_summary>To show non-inferiority EGRIFTA® vs. placebo development progression Diabetic Retinopathy HIV-infected subject concomitant abdominal lipohypertrophy Type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Diabetic Retinopathy HIV Subjects Treated With EGRIFTA®</brief_title>
	<detailed_description>To date , EGRIFTA® study longer 1 year human subject , EGRIFTA® study Type 2 diabetic HIV-infected subject receive oral hypoglycemic agent , GLP-1 analogue , insulin . The present study assess potential EGRIFTA® induce exacerbate DR HIV-infected subject antiretroviral therapy concomitant abdominal lipohypertrophy T2DM , explore long-term effect EGRIFTA® glycemic control major adverse cardiovascular event ( MACE ) population .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Inclusion criterion : 1 . Subject give write informed consent willing comply requirement protocol ; 2 . Subject adult man woman ( ≥ 18 year old ) ; 3 . Subject laboratory confirm HIV infection ; 4 . Subject receive ART stable least 8 week prior screen ; 5 . Subject physical evidence abdominal lipohypertrophy , determine examine study physician ; 6 . Subject T2DM determine previous HbA1c ≥ 6.5 % , previous fast plasma glucose ≥ 126 mg/dL ( 7.0 mmol/L ) , and/or previous 2hour plasma glucose ≥ 200 mg/dL ( 11.1 mmol/L ) oral glucose tolerance testing ( OGTT ) , and/or previous random plasma glucose ≥ 200 mg/dL ( 11.1 mmol/L ) symptom uncontrolled DM ; subject diagnose T2DM glucose lower medication great 1 year glucose parameter apply ; 7 . Subject , time screening , HbA1c 6.0 % 12.0 % ; 8 . Subject 's diabetes treat least 1 year diet alone , individual stable dose ( least 3 month ) insulin , OHA , GLP1 analogue plus insulin control diabetes permit HbA1C 6.0 % . OHA , GLP1 analogue , OHA/GLP1 analogue plus insulin accord current American Diabetes Association ( ADA ) guideline , dose stable least 3 month ; 9 . If subject use lipid lower drug , dose must stable least 2 month prior screen ; 10 . Subject must electrocardiogram ( ECG ) without clinically significant abnormality within 6 month prior screen ; 11 . Premenopausal woman childbearing potential eligible pregnant ( negative urine pregnancy test screen baseline ) lactate use acceptable form birth control prior study entry least 2 month complete treatment . Acceptable contraception define two barrier method , one barrier method spermicide , intrauterine device , oral contraceptive ; 12 . Women nonchildbearing potential must postmenopausal ( menses 1 year ) surgically sterile ( tubal ligation hysterectomy ) ; 13 . Women 40 year old must negative mammogram within 6 month prior screen mammogram take screening ; 14 . Men must normal prostate exam prostate specific antigen ( PSA ) Individuals stable dose ( least 3 month ) insulin , less equal 5 ng/mL within 6 month prior screen PSA , men 50 year age old , prostate specific antigen measure screen 1 . Subject Type 1 DM ; 2 . Subject body mass index ( BMI ) &lt; 18.5 kg.m2 ; 3 . Subject opportunistic infection acquire immune deficiency syndrome ( AIDS ) define illness within 3 month screen ; 4 . Subject malignancy , woman , personal family ( first degree relative ) history breast cancer . Exceptions basal cell carcinoma , situ carcinoma cervix , situ anal carcinoma , treat stable cutaneous squamous cell carcinoma . stable Kaposi 's sarcoma ; 5 . Preexisting PDR severe nonPDR ( NPDR ) , define ETDRS level ≥ 53 either eye ; 6 . Subject cytomegalovirus ( CMV ) retinitis , toxoplasmosis , ocular infection would prevent evaluation DR ; 7 . Subject previously treat DR ( treatment laser photocoagulation , intravitreal injection , vitrectomy ) ; 8 . Subject follow illnesses condition : 1. hypopituitarism , history pituitary tumor pituitary surgery ; 2. untreated hypothyroidism ; 3. head irradiation head trauma affect somatotropic axis ; 4. uncontrolled hypertension , define systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg ; 5. unstable CV condition , define : i. acute MI ; ii . unstable angina ; iii . decompensated congestive heart failure ( CHF , new onset exacerbation ) ; iv . stroke ; v. history within 6 month prior screen ; f. hepatic abnormality , define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ( 3 x ULN ) ; g. renal abnormality , define serum creatinine &gt; 2 x ULN ; h. lipid metabolism abnormality , define fast triglyceride &gt; 1500 mg/dL ; i. anemia , define hemoglobin ≤ 7 g/dL ; 9 . Drug hormone use follow 1 . Men : change regimen supraphysiological dose testosterone within 2 month prior screen ; 2. anabolic steroid , GH , GH secretagogue , GHRF product analog ( include EGRIFTA® ) , IGF1 , IGF bind protein 3 ( IGFBP 3 ) within 6 month prior screen ; 10 . Drug alcohol dependence within 6 month prior screen ; 11 . Subject use used anorectic , anorexigenics , antiobesity agent within 3 month prior screen ; 12 . Subject pregnant nursing ; 13 . Other significant disease , Investigator 's opinion , would exclude subject trial ; 14 . Participation , within 30 day prior screen , another clinical trial investigational agent could affect IGF1 level ; 15 . Known hypersensitivity study drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>